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a  b  s  t  r  a  c  t
Mexico  serves  as  a  global  model  for  advances  in rabies  prevention  and  control  in  dogs.  The  Mexican  Min-
istry  of Health  (MMH)  annual  application  of approximately  16 million  doses  of  parenteral  rabies  vaccine
has resulted  in significant  reductions  in  canine  rabies  during  the  past 20  years.  One  collateral  parameter
of rabies  programs  is  dog  population  management.  Enhanced  public  awareness  is  critical  to  reinforce
responsible  pet  ownership.  Surgical  spaying  and  neutering  remain  important  to  prevent  reproduction,
but  are  impractical  for achieving  dog  population  management  goals.  GonaConTM, an  anti-gonadotropin
releasing  hormone  (GnRH)  vaccine,  was  initially  tested  in captive  female  dogs  on  the  Navajo  Nation,
2008.  The  MMH  led this  international  collaborative  study  on  an  improved  formulation  of  GonaConTM
in  captive  dogs  with  local  representatives  in  Hidalgo,  Mexico  in  2011.  This  study  contained  20  bitches
assigned  to  Group  A (6  control),  Group  B (7  GonaConTM), and  Group  C  (7 GonaConTM and  rabies  vaccine).
Vaccines  were  delivered  IM.  Animals  were  placed  under  observation  and  evaluated  during  the  61-day
trial. Clinically,  all dogs  behaved  normally.  No  limping  or  prostration  was  observed,  in spite  of  minor
muscle  atrophy  post-mortem  in  the  left  hind  leg  of  dogs  that  received  GonaConTM. Two  dogs  that  began
the study  pregnant  give  birth  to healthy  pups.  Dogs  that  received  a  GonaConTM injection  had  macro  and
microscopic  lesions  consistent  with  prior  findings,  but  the  adverse  injection  effects  were  less  frequent
and lower  in intensity.  Both  vaccines  were  immunogenic  based  on  significant  increases  in  rabies  virus
neutralizing  antibodies  and  anti-GnRH  antibodies  in treatment  Groups  B  and  C. Simultaneous  adminis-
tration  of  GonaConTM and  rabies  vaccine  in  Group  C  did not  affect  immunogenicity.  Progesterone  was
suppressed  significantly  in  comparison  to  controls.  Future  studies  that  monitor  fertility  through  multiple
breeding  cycles  represent  a research  need  to determine  the  value  of  integrating  this  vaccine  into  dog
rabies  management.
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1. Introduction
Mexico is a global model for advances in rabies prevention and
control in dogs (Canis familiaris). During the past 20 years the Mexi-
can Ministry of Health (MMH)  has applied approximately 16 million
doses of parenteral canine rabies vaccine annually, resulting in a
substantial reduction in canine rabies [1,2]. This accomplishment
not only illustrates the effectiveness of these campaigns, but also
brings the elimination of canine rabies into focus as a potentially
achievable goal in developing countries. However, effective dog
population management is central to achieving that goal. Clearly,
enhanced public awareness is critical to reinforce the key role of
responsible pet ownership to reduce the risks associated with dog
overpopulation to human and animal health. Spaying and neutering
remain important components to prevent unwanted reproduction,
but they are expensive, invasive, time consuming and impractical
for achieving broader dog population management goals integral
to canine rabies elimination [1,3]. Fertility control holds promise
as an efficient and less invasive method in rabies management in
Mexico and perhaps globally.
México maintains a close relationship with the U. S. Department
of Agriculture (USDA), Animal and Plant Health Inspection Service
(APHIS) through the North American Rabies Management Plan,
signed by representatives of Canada, Mexico, the Navajo Nation
and the U.S. in 2008. This plan serves as a basis for collabora-
tions to develop, study and implement methods and strategies to
enhance rabies management. The immunocontraceptive vaccine
GonaConTM represented an ideal candidate for evaluation in cap-
tive dogs in Mexico [4,5]. Results from this study should provide a
foundation for continued evaluation of GonaConTM as a prospective
method for dog population management.
The MMH  and USDA, APHIS, Wildlife Services (WS), with tech-
nical support of many partners, collaborated in a study of a new
formulation of GonaConTM in captive dogs in Mexico. The study
was conducted in Hidalgo State in collaboration with State Health
Services, and invited institutions and groups. The primary objec-
tives were to: (1) determine the immunogenicity of simultaneous
IM administration of GonaConTM and rabies vaccine and (2) assess
potential adverse health effects in dogs, including injection site
reactions from this new vaccine formulation.
2. Materials and methods
2.1. GonaConTM and canine rabies vaccine
GonaConTM is an immunocontraceptive vaccine (USDA, APHIS,
Wildlife Services (WS), National Wildlife Research Center (NWRC),
Fort Collins, CO, USA) consisting of mammalian gonadotropin
releasing hormone (GnRH) conjugated to a large mollusk hemo-
cyanin protein and emulsified with the adjuvant AdjuVacTM. Unlike
prior GonaConTM formulations, the one used in this study was
produced in a clean room to reduce the chance of particulate
contamination and Gentamicin and Fungizone (Life Technologies,
Carlsbad, CA) were added to inhibit bacterial and fungal activ-
ity. Each 0.5 ml  dose contained 500 g of the GnRH conjugate
and 21 g of inactivated Mycobacterium avium in the adjuvant.
GonaConTM was stored and shipped under refrigerated conditions
in pre-loaded, 3 ml  Air-Tite luer-lock syringes (Air-Tite Products,
Virginia Beach, VA, USA) [5].
A commercial inactivated rabies virus vaccine was administered
(Rabiffa, Merial Inc., El Marques, Qro., Mexico) that is commonly
used by the State Health Services during the National Weeks of
Dog Rabies Vaccination in accordance with Mexican Regulations.
By special request from the MMH,  the rabies vaccine was supplied
Fig. 1. Stray dogs housed and cared for at PROVEZA’s Shelter and Refuge (Cerrada 16
de  Septiembre s/n Colonia Centro, Villa de Tezontepec, C.P. 43882, Hidalgo, Mexico)
included in Group B of the GonaConTM study in Mexico 2011.
Photo taken by Dr. Luis Lecuona.
in 20 ml  vials containing 20 dosages (1 ml/dose), stored at 4 ◦C until
ready for use [6].
2.2. Vaccine administration
Vaccines were administered once IM throughout this study in
the upper right hind leg (rabies vaccine) or upper left hind leg
(GonaConTM). A 3 ml  disposable syringe and 21 G × 38 mm needle
were used to administer vaccines.
2.3. Experimental animals
Twenty female dogs of mixed breeds were collected from
September to November 2010 for this trial. Six owned bitches
came from the Villa de Tezontepec County, in Hidalgo State. The
6 owners signed an authorization for inclusion of their dogs in the
study. Fourteen other bitches were collected at dog round-ups con-
ducted by the Canine Attention Centers from the Sanitary Regions
of Pachuca and Tulancingo in Hidalgo State. Typically, unclaimed
dogs at the Canine Attention Centers are euthanized in a 48–72 h
post round-up pursuant to the National Animal Control Regulation
(NOM-042-SSA2-2006. Number 4.2.14, Section 4.2.) [7]. Fourteen
bitches over 1 year old were selected from this source for this study.
Dogs were selected based size (medium or large), apparent healthy
clinical status and general body condition. Dogs were held for a
60-day observation and adaptation period.
Six bitches in Group A were confined at the home of their
owner. The other 14 bitches were divided into vaccination Group B
(GonaConTM) or Group C (GonaConTM and rabies). These groups
included 7 animals maintained in communal kennels in the
PROVEZA’s Shelter and Refuge (Cerrada 16 de Septiembre s/n Colo-
nia Centro, Villa de Tezontepec, C.P. 43882, Hidalgo, Mexico; 19◦
52′ 45.33 N, 98◦ 49′ 13.36′′ W)  (Fig. 1). This facility offered com-
plete dog holding support during this study. Each bitch was  marked
with a collar and unique numbered tag for identification. Animal
care personnel maintained the kennels twice/day. Dogs were fed a
commercial dog food (Adult Natural Balance Pedigree, Mars Inc.,
Mexico) and water ad libitum. All female dogs were evaluated
by veterinarians, State Health Services, Hidalgo during the 61-day
study.
The 6 owned bitches chosen for Group A were vaccinated
with the rabies vaccine. The 14 female dogs maintained in the
PROVEZA’s Shelter and Refuge were randomly assigned to two
treatment groups. Group B included 7 dogs that were vaccinated
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with GonaConTM immunocontraceptive vaccine. Group C included
7 dogs that were simultaneously vaccinated with GonaConTM and
the rabies vaccine. The 61-day observation period for dogs during
the trial ended on March 11, 2011.
2.4. Blood samples collection
Blood samples were obtained on days 0, 31 and 61. Blood was
drawn from the external jugular vein using a 10 ml  disposable
syringe with a 20 G × 38 mm needle, or from the radial vein using
BD VacutainerTM 13 mm × 75 mm  tubes, with 20 G needles. Sam-
ples for complete blood counts (CBC) were collected in EDTA BD
VacutainerTM tubes. Samples for blood chemistry profiles (BCP),
progesterone (THR), rabies virus neutralizing antibodies (VNA) and
anti-gonadotropin releasing hormone (GnRH) antibodies were col-
lected in SST BD VacutainerTM tubes for serum separation.
Blood samples were stored on ice in an insulated container until
their arrival at the Clinical Laboratory of the Tizayuca’s Sanitary
Region in Hidalgo State. Samples for CBC and BCP were processed
in a 4-h period. Samples for THR, VNA and GnRH were centrifuged.
Serum was separated and stored in CryoTubesTM (Nalge Nunc Inter-
national, Rochester, NY, USA) at −70 ◦C until analyzed.
2.5. Clinical evaluation of the dogs
Veterinary Personnel from the Hidalgo State Health Services
performed daily and weekly clinical evaluations of dogs.
2.6. Determination of CBC and BCP
Dogs were evaluated for CBC and BCP as indicators of their health
status [8]. For CBC, 6 values were considered: hematocrit value
(HCT), hemoglobin concentration (HGB), mean corpuscular volume
(MCV), mean corpuscular hemoglobin (MCH), total leukocyte vol-
ume  (LEU) and platelet count (PLT). These values were determined
utilizing a Coulter Counter (Coulter S Plus IV., Coulter Electronics
Inc., Hialeah, FL 33010, USA). For BCP, 5 values were considered:
glucose (GLU), blood urea nitrogen (BUN), creatinine (CREA), Uric
Acid and Cholesterol. All were determined with a multichannel bio-
chemical analyzer (Discrete Analyzer Continues Optical Scanner
[DACOS], Coulter Corporate Communications, Hialeah, FL, USA).
2.7. Determination of THR
Progesterone levels were determined at the NWRC. Plasma pro-
gesterone levels were assayed by the coat-a-tube RIA method
(Diagnostic Products, Los Angeles, CA, USA). The antigen–antibody
complex is determined with a gamma  spectrophotometer [9].
2.8. Determination of rabies VNA titers
Rabies VNA titers were determined by the National Center of
Animal Health Diagnostic Services (CENASA/SENASICA/SAGARPA).
The Fluorescent Antibody Virus Neutralizing (FAVN) test, an adap-
tation of the Rapid Fluorescent Focus Inhibition Test (RFFIT) [10,11],
was conducted on tissue culture 96-well microplates using BHK2l-
13s (ATCC CCL-10) cells and the CVS 11 strain of rabies virus (ATCC
VR 959). A virus titer of 10 TCID50/ml. EMEM-10% FCS was used as a
diluent for control and test sera, and for the challenge virus. Serial
3-fold dilutions of the positive and negative serum controls and test
sera were prepared in microplate wells in 0.1 ml  volumes. The well
was considered negative if no fluorescent cells were observed. The
well was considered positive if one or more fluorescent cells were
observed. The serum titers were expressed in I.U./ml by comparison
with the titer of the standard serum in each test. The validity of each
test was then assessed by recording results obtained from titra-
tions of CVS (TCID50), naive serum (D50) and the positive standard
(D50) on control charts. Each test was  considered valid if the values
found for all of these controls were not statistically different from
the respective means of the values obtained from all previous tests
[12,13]. The FAVN end point was adjusted to 13.8 I.U./ml.
2.9. Determination of anti-GnRH titers
Anti-GnRH titers were determined at the NWRC. An enzyme-
linked immunosorbent assay (ELISA) was used to measure
anti-GnRH antibody titers. A 96-well plate was prepared by adding
100 ng of BSA-GnRH antigen to each well and then blocking with
SeaBlockTM. Fifty microliters of serially diluted serum was  used for
each assay. Anti-GnRH antibody was  determined by adding rabbit
anti-dog IgG to each well, washing, then adding goat anti-rabbit IgG
labeled with horse-radish peroxidase (HRP), washing, then devel-
oping a color by adding a HRP substrate. The color was  proportional
to the anti-GnRH antibody titer. BSA-GnRH was  added to the ELISA
plate, causing only antibodies to GnRH to be detected [14].
2.10. Post-mortem evaluations
Macro and microscopic reactions to GonaConTM were evaluated
for 17 female dogs euthanized to characterize potential variabil-
ity. The sample included 6 dogs that served as GonaConTM controls
for macro and microscopic effects. In addition, 5 of the 7 female
dogs from Group B and 6 of the 7 female dogs from Group C
were included in the sample. Procedures recommended [15–17]
and established by the Mexican Official Regulation (NOM-033-
ZOO-1995. CONASA/SAGARPA) [18] were applied. All dogs were
sedated with Xylazine 2% (4.4 mg/kg, 20 mg/ml. PorcinTM, PISA
Agropecuaria SA de CV. REG. SAGARPA Q7833-009) administered
intramuscularly to the upper right hind leg with a disposable
3 ml  syringe and 21 G × 38 mm needle. Under sedation, an over-
dose of pentobarbital (over 40 mg/kg, 0.063 gr/ml, SedalpharmaTM,
Pet’s Pharma de México, S.A. de C.V. REG. SAGARPA Q-7972-004)
was  applied in the radial vein of the right forearm using a 10 ml
disposable syringe with a 20 G × 38 mm needle. Necropsies were
performed according to routine standards [19].
During necropsy samples taken from skeletal muscle at the
GonaConTM injection site, ovaries and pituitary glands were fixed
in formaldehyde (4% PBS). Fixed tissues were embedded in paraf-
fin, prepared in 5 m sections on slides and stained with H&E [20].
Slides were analyzed with an Olympus BX41 microscope; images
were captured with a digital ProEvolution Camera in Image-Pro
Express 6.0 (MediaCybernetics).
2.11. Statistical methods
MINITAB Statistical software was  used (MINITAB INC 13.1). A 1-
way, unstacked ANOVA and Turkey’s test were used for the analysis.
Statistical significance was set at P < 0.05 [21].
3. Results
3.1. Clinical evaluation
Dogs in Group A were clinically healthy. One of 6 dogs showed
external vaginal swelling (heat) at D58. No physical abnormali-
ties, prostration, injuries or limping were reported. Two dogs in
Group A finished the study pregnant. Average weight on D0  was
21.2 ± 10.5 kg(SD); on D61 it was 21.3 ± 10.7 kg(SD).
During week 1, 4 of 7 dogs (57.1%) in Group B showed signs
of pain based on an extension and flexing test of the left leg and
hyperthermia in the left leg. Pain began to subside during week
1 and was not noticeable by week 2. One dog had puppies before
the beginning of the study. Two dogs had puppies during week 1.
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Table 1
Complete blood counts (CBC) and blood chemistry profiles (BCP) in female dogs by Group and Day.
Group/Day Group A Group B Group C
Lab findings D0 D31 D61 D0 D31 D61 D0 D31 D61
CBC
Erythroblastopenia 2 3 0 1 0 0 0 0 0
Leukocytosis 1 0 0 0 0 0 1 0 0
Leukopenia 1 1 0 7 2 1 0 2 1
Thrombocytopenia 6 1 2 7 1 4 6 0 3
Polycythemia 0 0 2 0 1 3 1 0 2
BCP
Hypoglycemia 4 1 0 1 1 0 3 0 0
Hyperazotemia 6 6 5 5 6 7 7 7 7
Hypercholesterolemia 1 0 1 0 0 0 0 0 0
Hypocholesterolemia 0 0 0 0 2 0 0 2 0
Hypouremia 0 0 0 0 0 0 0 0 2
Table 2
Mean and standard deviation for progesterone (THR ng/ml) in female dogs by Group and Day.
Group/Day Group A Group B Group C
Lab findings D0 D31 D61 D0 D31 D61 D0 D31 D61
<1.0 2 4 1 5 7 7 3 7 7
=1.0  3 1 0 1 0 0 0 0 0
>1.0  1 1 5 1 0 0 4 0 0
Statistical findings
Mean 1.71 5.82 31.04 0.90 0.08 0.23 7.52 0.31 0.26
St  dev 2.98 14.14 54.69 1.75 0.14 0.31 12.48 0.23 0.32
One dog had a small swelling at the GonaConTM application site
beginning on D16 until the end of the study. All dogs concluded the
study with minor muscle atrophy in the left leg that was percepti-
ble by clinical evaluation; however, no prostration or limping was
reported. Average weight on D0 was 15.3 ± 5.3 kg(SD); on D61 it
was 13.9 ± 3.4 kg(SD).
Not unlike Group B, 2 of 7 female dogs (28.5%) in Group C
showed similar signs of pain and hyperthermia in the left leg. Again,
pain was not noticeable by week 2. One dog had external vagi-
nal swelling only at D16 and D59, unrelated to heat. One dog had
slight swelling at the GonaConTM application site beginning at D16
that persisted through the study. All dogs concluded the study with
minor muscle atrophy in the left leg that was perceptible by clini-
cal evaluation, but no prostration or limping was reported. Average
weight on D0 was 15.7 ± 4.6 kg(SD) on D61 it was  15.9 ± 4.1 kg(SD).
3.2. CBC and BCP
All dogs had one or more clinical and metabolic changes in CBP
and BCP. This is noteworthy given visible clinical changes were not
observed; all dogs had suggestions of chronic disease and metabolic
deficiencies (Table 1).
3.3. Progesterone
At Day 0, THR levels in Groups A and B were lower than Group
C (F = 1.64, P = 0.222). At Day 31 THR levels in Groups B and C were
significantly lower than Group A (F = 1.11, P = 0.0351), which did
not receive GonaConTM. At Day 61, THR levels in Groups B and C
were equal and lower than Group A (F = 2.22, P = 0.137) (Table 2).
3.4. Rabies VNA titers
All dogs were reported to have been rabies vaccinated; dogs
in Group B were not revaccinated against rabies. At Day 0, rabies
VNA titers in Groups A and C were similar, but lower than Group
B (F = 2.46, P = 0.116). At Day 31, rabies VNA titers in Group B were
lower than Group A. Also, Group C titers were lower than Group B
(F = 3.01, P = 0.076). At Day 61, rabies VNA titers in Groups B and C
were lower than Group A (F = 3.92, P = 0.040) (Tables 3 and 4).
3.5. Anti-GnRH antibody titers
GonaConTM was  never used in these dogs before this study. At
Day 0, no anti-GnRH immune response was detected. At Day  31,
anti-GnRH titers among dogs in Groups B and C were similar, but
higher than Group A (F = 18.19, P = 0.0001). The same results were
observed on Day 61 (F = 10.27, P = 0.001) (Table 5).
3.6. Macro and microscopic observations
Six dogs in control Group A had no apparent abnormalities in
their pituitary glands and skeletal musculature of their legs. Several
atresic follicles were identified in the ovaries.
Four dogs in Group B showed slight diffuse edema and conges-
tion in their pituitary glands. One sample had coagulative necrosis
with basophilic cells and an increase in acidophilic cells. Three of
Table 3
Rabies virus neutralizing antibodies (VNA) by I.U. class for female dogs by Group and Day.
Group/Day Group A Group B Group C
Findings (IU/ml) D0 D31 D61 D0 D31 D61 D0 D31 D61
<0.5 1 0 0 1 2 1 3 0 1
0.5–3.0 2 0 0 0 0 0 1 0 0
>3.0  3 6 6 6 5 6 3 7 6
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Table  4
Mean and standard deviation for rabies virus neutralizing (VNA) levels for female dogs by Group and Day.
GROUP/DAY Group A Group B Group C
Statistical findings D0 D31 D61 D0 D31 D61 D0 D31 D61
Mean 6.34 13.77 13.77 10.60 8.59 7.67 4.54 11.14 8.12
St  dev 5.71 0.0 0.0 4.38 5.21 4.85 5.60 3.69 5.38
Table 5
Number of dogs with anti-GnRH antibodies by Group and Day.
GROUP/DAY Group A Group B Group C
Lab findings D0 D31 D61 D0 D31 D61 D0 D31 D61
0 6 6 6 7 0 1 7 1 1
1/8  0 0 0 0 0 1 0 0 0
1/16  0 0 0 0 0 1 0 0 0
1/128  0 0 0 0 6 4 0 1 6
1/256 0 0 0 0 1 0 0 5 0
5 dogs showed no apparent changes in the skeletal muscles of
their right and left hind legs. One of the other 2 dogs sampled
showed moderate and focal chronic granulomatous myositis. The
remaining dog showed diffuse coagulative necrosis.
Four of 6 dogs in Group C showed slight diffuse congestion
in their pituitary glands. Three dogs also had diffuse edema. All
samples showed coagulative necrosis with basophilic cells and an
increase in acidophilic cells. Skeletal muscles of the right leg of 5
dogs had no apparent changes, but 2 of 5 left legs showed slight
focal chronic granulomatous myositis. The other 3 had moderate
to severe multifocal chronic myositis.
Overall, basophilia of the tunica ambuginea, atresic follicles and
reduction of the second, preatrium, and third follicles, were iden-
tified in ovary samples from 5 dogs in Group B and 6 dogs in Group
C.
4. Discussion
Dogs in this study remained healthy, but serum analysis indi-
cated chronic conditions and metabolic alterations associated with
hepatic and renal functions. Additional analysis is necessary to
determine if these conditions were a function of prior parasite loads
and if they would have a measurable effect on the results. Because
dogs in the study had previously received rabies vaccine, this value
became the baseline for the control group. The administration of
GonaConTM vaccine resulted in a reduction of progesterone and
high anti-GnRH antibody titers. No toxicity was reported in dogs
treated with GonaConTM, but further study may  be warranted to
determine if the metabolic status of the dogs is an important cri-
terion in their immune response. These results were similar to
a previous study [5] in that the simultaneous administration of
GonaConTM and rabies vaccine in female dogs did not limit the
immunogenicity of either vaccine.
During the 4 final days of this study, clinical evaluation detected
apparent muscle atrophy at the injection site in 2 dogs from Group
B and 5 dogs from Group C. Although systematic measurements
were lacking over time, observations showed that the diameter of
the muscles in the left leg was less than in the right leg. This appar-
ent muscle atrophy near the GonaConTM injection site was likely
related to the chronic granulomatose myositis and diffuse coagu-
lative necrosis reported in those animals after necropsy at D61. No
limping, ulceration or paralysis was observed in these dogs. The
number, type and intensity of adverse local reactions was  lower
than previously reported [22–24].
Two dogs in Group B, and 1 in Group C that began the
study pregnant had puppies at D61. These dogs remained
healthy throughout the study, providing supporting evidence that
GonaConTM would not negatively affect existing pregnancies if this
vaccine was used operationally.
The findings of this study are encouraging and advance our
understanding of an improved formulation of GonaConTM. Addi-
tional studies to evaluate formulations that result in fewer local
injection site effects while also reducing fecundity remain essen-
tial to move toward field use of GonaConTM in Mexico during mass
rabies vaccination campaigns. Moreover, additional monitoring of
the effects of GonaConTM on fertility through multiple breeding
cycles (e.g., in owned dogs for 2 years) in the presence of repro-
ductively competent male dogs remains critical to determine the
complementary population management value of integrating this
vaccine or perhaps other immunocontraceptives into dog rabies
management. We  contemplate future studies and offer encourage-
ment to others to take similar initiatives in the interest of enhancing
canine rabies management through the integration of less invasive,
more efficient and effective dog population management methods
in the future [25].
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